Rein Therapeutics (RNTX) Competitors $1.94 +0.01 (+0.52%) As of 05/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock RNTX vs. RNAZ, CRGX, CRDF, ADCT, YMAB, KOD, NBTX, VYGR, OGI, and INMBShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include TransCode Therapeutics (RNAZ), CARGO Therapeutics (CRGX), Cardiff Oncology (CRDF), ADC Therapeutics (ADCT), Y-mAbs Therapeutics (YMAB), Kodiak Sciences (KOD), Nanobiotix (NBTX), Voyager Therapeutics (VYGR), Organigram (OGI), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. TransCode Therapeutics CARGO Therapeutics Cardiff Oncology ADC Therapeutics Y-mAbs Therapeutics Kodiak Sciences Nanobiotix Voyager Therapeutics Organigram INmune Bio Rein Therapeutics (NASDAQ:RNTX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Is RNTX or RNAZ more profitable? Rein Therapeutics' return on equity of -74.08% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -74.08% -27.93% TransCode Therapeutics N/A -649.03%-281.34% Does the MarketBeat Community favor RNTX or RNAZ? TransCode Therapeutics received 16 more outperform votes than Rein Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRein TherapeuticsN/AN/ATransCode TherapeuticsOutperform Votes1694.12% Underperform Votes15.88% Do analysts rate RNTX or RNAZ? TransCode Therapeutics has a consensus target price of $280.00, suggesting a potential upside of 3,426.45%. Given TransCode Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TransCode Therapeutics is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, RNTX or RNAZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$15.73M-$2.86-0.68TransCode TherapeuticsN/AN/A-$18.55MN/AN/A Do insiders & institutionals believe in RNTX or RNAZ? 90.9% of Rein Therapeutics shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, RNTX or RNAZ? Rein Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Does the media favor RNTX or RNAZ? In the previous week, Rein Therapeutics had 3 more articles in the media than TransCode Therapeutics. MarketBeat recorded 4 mentions for Rein Therapeutics and 1 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.50 beat Rein Therapeutics' score of -0.75 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryRein Therapeutics beats TransCode Therapeutics on 7 of the 12 factors compared between the two stocks. Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.98M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-0.628.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book1.386.466.794.50Net Income-$15.73M$143.98M$3.23B$248.18M7 Day Performance-17.80%2.03%1.53%0.20%1 Month Performance4.86%4.11%10.06%12.37%1 Year PerformanceN/A-2.87%16.72%7.04% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein TherapeuticsN/A$1.94+0.5%N/AN/A$42.98MN/A-0.629Earnings ReportGap DownRNAZTransCode Therapeutics2.2611 of 5 stars$8.16+6.7%$280.00+3,331.4%-100.0%$190.46MN/A0.009Positive NewsEarnings ReportCRGXCARGO Therapeutics2.1895 of 5 stars$4.12+3.3%$15.00+264.1%-79.8%$189.97MN/A-0.97116CRDFCardiff Oncology1.5614 of 5 stars$2.81+2.2%$12.00+327.0%-18.1%$186.94M$587,000.00-2.9920Gap UpADCTADC Therapeutics2.6699 of 5 stars$1.88+10.9%$7.75+313.3%-47.6%$185.96M$70.84M-0.78310Analyst RevisionYMABY-mAbs Therapeutics3.4449 of 5 stars$4.10+6.2%$16.70+307.3%-67.4%$185.64M$87.69M-7.59150Analyst ForecastAnalyst RevisionGap UpKODKodiak Sciences3.6815 of 5 stars$3.50+5.1%$9.00+157.1%+10.3%$184.63MN/A-0.9690Analyst RevisionNBTXNanobiotix1.6897 of 5 stars$3.89+5.9%$8.00+105.9%-47.2%$183.11M$-11,609,000.000.00100News CoverageVYGRVoyager Therapeutics4.6568 of 5 stars$3.30+0.6%$13.39+305.8%-62.7%$182.61M$66.96M4.65100Gap UpOGIOrganigram0.2575 of 5 stars$1.36+9.7%N/A-30.2%$182.02M$166.12M-3.58860High Trading VolumeINMBINmune Bio1.9353 of 5 stars$7.86+7.8%$22.80+190.1%-29.4%$180.65M$50,000.00-3.6110Gap Up Related Companies and Tools Related Companies RNAZ Competitors CRGX Competitors CRDF Competitors ADCT Competitors YMAB Competitors KOD Competitors NBTX Competitors VYGR Competitors OGI Competitors INMB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
